After Hours
There may be slightly higher risks associated with pre-market and after-hours trading than during regular market hours. Due to the fact that issuers often announce critical financial information outside of regular trading hours, extended-hours trading may result in wider spreads for particular securities. Earlier, Yahoo Finance discussed this stock as it revealed Cytokinetics to Announce Fourth Quarter Results on February 27, 2024.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Stocks Info
As a NASDAQ listed company, CYTK falls under the Healthcare sector while operating within the Biotechnology industry segment. The current market capitalization of Cytokinetics Inc is $7.75B. A total of 1.79 million shares were traded on the day, compared to an average of 3.63M shares.
Insider Activity
Aside from predicting where a stock will go, investors also consider insider trades as an indicator of the stock’s future direction. During the recent three months, CYTK has seen 2 BUY and 2 SELL insider trades, representing the acquisition of 10,000 and the disposition of 10,000 shares. Over the last 12 months, there were 58 BUYs and 44 SELLs from insiders. Insiders purchased 492,654 shares during that period but sold 353,346.
In the most recent transaction, HENDERSON JOHN T sold 5,000 shares of CYTK for 76.48 per share on Feb 14. After the transaction, the Director now owns 42,632 company shares. In a previous transaction on Feb 13, Blum Robert I sold 12,500 shares at 76.85 per share. CYTK shares that President & CEO owns now total 441,797.
Among the insiders who sold shares, Malik Fady Ibraham disposed of 32,605 shares on Feb 06 at a per-share price of $79.30. This resulted in the EVP Research & Development holding 142,973 shares of CYTK after the transaction. In another insider transaction, Blum Robert I sold 12,500 shares at $79.57 per share on Jan 31. Company shares held by the President & CEO now total 441,797.
In spite of price targets being rarely accurate, it tends to exert some kind influence from time to time, and was often accepted by the market as having some value. According to analysts who have offered 12-month price targets for CYTK in the last 3 months, the mean price target is $93.97 with high estimates of $122.00 and low estimates of $42.40. In terms of 52-week highs and lows, CYTK has a high of $110.25 and a low of $25.98.
As of this writing, CYTK has an earnings estimate of -$0.97 per share for the current quarter. EPS was calculated based on a consensus of 17 estimates, with a high estimate of -$0.38 per share and a lower estimate of -$1.47. The company reported an EPS of -$1.34 in the last quarter, which was -16.50% lower than expectations of -$1.15.
Balance Sheet Annually/Quarterly
The balance sheet of a company shows what assets and liabilities a company has, as well as the amount, equity investors have invested. With the help of this information, a company’s financial ratios can be calculated to give investors an overview of the company’s prospects. CYTK’s latest balance sheet shows that the firm has $471.64M in Cash & Short Term Investments as of fiscal 2021. There were $269.93M in debt and $71.86M in liabilities at the time. Its Book Value Per Share was -$4.56, while its Total Shareholder’s Equity was $243.86M.
Analysts Opinion
The risks associated with pre-market and after-hours trading may be slightly higher than the regular market hours. The reason is that extended-hours trading may result in wider spreads for particular security due to lower liquidity and higher volatility as issuers often announce critical financial information outside regular trading hours. Currently, 0 analysts are providing their opinions on the stock. On a scale of 1 to 5, with 1 being Sell and 5 being Buy, the average analyst rating for CYTK is Buy with a score of 4.53.
